Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

More PhIII Success For Acacia's Dopamine Antagonist In PONV

This article was originally published in Scrip

Executive Summary

Acacia Pharma's goal of returning dopamine antagonists to the arsenal of treatments available for post-operative nausea and vomiting (PONV) has experienced another boost following positive results from a second Phase III study, this time evaluating the use of lead product Baremsis as a prophylaxis in combination with standard antiemetics for the prevention of PONV in high-risk patients.


Related Content

Acacia Pharma's Antiemetic Baremsis A Step Closer to US Filing